X

Trial Profile

An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 05 Mar 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dapsone (Primary)
Indications Acne vulgaris
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors Allergan

Most Recent Events

10 Sep 2019 According to an Almirall media release, based on the data from thsi study, the FDA has approved Aczone 7.5% Gel , for the expanded indication to include patients aged 9-11 for the topical treatment of Acne vulgaris.
11 Jun 2018 Status changed from recruiting to completed.
11 Nov 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com